Delcath (DCTH): Utang-utang marang kapitalisasi buku

Logo grafis Delcath Systems Inc (DCTH)

The market capitalization trend for Delcath Systems, Inc. (DCTH) reflects dynamics based on the development of blood filtration systems for localized liver treatment, which reduces overall therapy toxicity. Production stability is ensured through the creation of component reserves, eliminating assembly downtime. The current metric stands at 0.02, while the business relies on the closed CHEMOSAT ecosystem, which strictly binds clinics to brand regulations.

Delcath Systems, Inc. (DCTH) - Utang-utang marang nilai buku saka 04.07.2022 nganti 27.10.2026
Barang utama Delcath Systems Inc

This ratio determines the company's degree of dependence on borrowed funds by comparing total liabilities to equity to assess default risks and the efficiency of financial leverage. By analyzing the dynamic trend of financial leverage on the balance sheet, an investor can see how Delcath Systems, Inc. (DCTH) balances its debt load against the resources required for the commercialization of liver cancer treatment systems during the regulatory approval period.

Karo sapa Delcath Systems, Inc. saingan

ONC - Rasio utang marang kapitalisasi buku|Rasio utang marang nilai buku halozyme.com HALO|RVMD: Utang-utang marang kapitalisasi buku|AAPG - Utang marang nilai buku|Utang-utang marang kapitalisasi buku CGON|URGN (UroGen Pharma Corp) - Utang-utang marang nilai buku|BCAX - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik personalis.com (PSNL)|Erasca (ERAS) - Utang marang nilai buku|Rasio utang marang aset resik Y-mAbs Therapeutics Inc (YMAB)|Aura Bio - Utang-utang marang kapitalisasi buku|CADL - Utang marang nilai buku|Accuray Incorporated - Utang marang nilai buku|SLS: Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Actuate Therapeutics ACTU|Citius Oncology Inc. (CTOR) - Rasio utang marang aset resik|Utang-utang marang kapitalisasi buku HURA (TuHURA Biosciences Inc.)|Utang-utang marang nilai buku Protara Tx|Utang-utang marang kapitalisasi buku Fate Therapeutics, Inc. FATE|Rasio utang marang nilai buku aadibio.com (WHWK)|TCRX: Utang-utang marang kapitalisasi buku|Champions Oncology Inc - Utang-utang marang nilai buku|XBIT - Rasio utang marang kapitalisasi buku|CVM - Rasio utang marang kapitalisasi buku|OSTX (OS Therapies Incorporated) - Utang-utang marang kapitalisasi buku|radiopharmtheranostics.com (RADX) - Utang marang nilai buku|ARTV (Artiva Biotherapeutics Inc.) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku Adlai Nortye Limited (ANL)|Utang marang nilai buku Veru Pharma|Utang marang modal buku Tempest Therapeutics Corp (TPST)|Utang-utang marang kapitalisasi buku Xilio Therapeutics|RENB - Rasio utang marang aset resik|Utang marang nilai buku Mural Bio (MURA)|KAPA: Rasio utang marang aset resik|onkuretherapeutics.com - Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik CytoMed Therapeutics Limited|Utang marang nilai buku CRIS (Curis Inc.)|Utang-utang marang nilai buku APLM|THAR (Tharimmune) - Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik advanbiomed.com ADVB|Utang marang nilai buku Genprex, Inc (GNPX)|Utang marang modal buku Calidi Biotherapeutics Inc. CLDI|SBFM (Sunshine Biopharma, Inc.) - Utang-utang marang kapitalisasi buku|XBIO: Utang-utang marang nilai buku|SLRX (Salarius Pharmaceuticals, Inc.) - Rasio utang marang kapitalisasi buku|PPBT (Purple Biotech Ltd) - Utang marang nilai buku|AONC: Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik BeiGene Ltd (BGNE)|Checkpoint Therapeutics (CKPT) - Utang marang nilai buku|Rasio utang marang aset resik elevationoncology.com (ELEV)|Utang-utang marang kapitalisasi buku ICAD|Ikena Oncology Inc. - Utang-utang marang aset resik|Notable Labs Inc. (NTBL) - Rasio utang marang kapitalisasi buku|VIRX - Rasio utang marang nilai buku|MOR (MorphoSys AG) - Utang-utang marang kapitalisasi buku|Utang marang nilai buku nayabiosciences.com|AAPGV: Utang marang nilai buku